利沃西门丹,在心脏性休克中是一个有前途的药物治疗:全面的审查
Hendri Susilo1,2, Fan Maitri Aldian3, Citrawati Dyah Kencono Wungu4,5
1Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga Surabaya, Indonesia.
European cardiology
|November 26, 2024
概括
莱沃西门丹为心脏性休克 (CS) 提供了有前途的治疗方法,可以改善存活率和血液动力学,而不会增加心肌氧需求. 本综述强调了它在管理CS方面的优势,而不是传统的内类药物.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 心脏性休克 (CS) 是一种危及生命的疾病,死亡率高.
- 目前对CS的管理策略面临重大挑战,需要新的治疗方法.
研究的目的:
- 综合审查levosimendan在心脏病性休克管理中的有效性和安全性.
- 为了比较levosimendan与在CS治疗中使用的传统无otropic药物.
主要方法:
- 系统审查和综合来自众多研究的证据.
- 对levosimendan进行比较分析,并将其与埃诺西蒙,多布他胺,多巴胺和北上腺素进行比较.
- 对安全概况和不良影响进行批判性评估.
主要成果:
- 莱沃西门丹可以增强心肌收缩性,而不会增加氧气需求,这是CS管理中的独特机制.
- 对比研究表明,levosimendan在改善生存率和血液动力学参数方面的优势.
- 与传统药物相比,Levosimendan显示了CS并发症的减少.
结论:
- 莱沃西门丹代表了心脏性休克的有价值的治疗选择.
- 该药物显示出在CS管理中改善患者结果的潜力.
- 它的独特机制和证明的好处支持其在临床实践中的作用.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
386
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
386
Heart Failure Drugs: Inotropic Agents
521
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
521
Heart Failure Drugs: β-Blockers
316
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
316
Heart Failure Drugs: Diuretics
343
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
343
Blood Pressure Imbalances and Circulatory Shock
753
Disorders affecting blood volume, vascular tone, or vascular function can disrupt vascular homeostasis, including conditions like hypertension, hemorrhage, and shock.
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
753
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.2K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.2K


